Ho Gilbert, Lam Linh, Tran Tony, Wei Jianshe, Hashimoto Makoto
PCND Neuroscience Research Institute, Poway, CA, United States.
Institute for Brain Sciences Research, School of Life Sciences, Henan University, Kaifeng, China.
Front Cell Dev Biol. 2024 Jul 12;12:1430593. doi: 10.3389/fcell.2024.1430593. eCollection 2024.
In Alzheimer's Disease (AD), amyloidogenic proteins (APs), such as β-amyloid (Aβ) and tau, may act as alarmins/damage-associated molecular patterns (DAMPs) to stimulate neuroinflammation and cell death. Indeed, recent evidence suggests that brain-specific type 2 immune networks may be important in modulating amyloidogenicity and brain homeostasis. Central to this, components of innate neuroimmune signaling, particularly type 2 components, assume distinctly specialized roles in regulating immune homeostasis and brain function. Whereas balanced immune surveillance stems from normal type 2 brain immune function, appropriate microglial clearance of aggregated misfolded proteins and neurotrophic and synaptotrophic signaling, aberrant pro-inflammatory activity triggered by alarmins might disrupt this normal immune homeostasis with reduced microglial amyloid clearance, synaptic loss, and ultimately neurodegeneration. Furthermore, since increased inflammation may in turn cause neurodegeneration, it is predicted that AP aggregation and neuroinflammation could synergistically promote even more damage. The reasons for maintaining such adverse biological conditions which have not been weeded out during evolution remain unclear. Here, we discuss these issues from a viewpoint of amyloidogenic evolvability, namely, aEVO, a hypothetic view of an adaptation to environmental stress by AP aggregates. Speculatively, the interaction of AP aggregation and neuroinflammation for aEVO in reproduction, which is evolutionally beneficial, might become a co-activating relationship which promotes AD pathogenesis through antagonistic pleiotropy. If validated, simultaneously suppressing both AP aggregation and specific innate neuroinflammation could greatly increase therapeutic efficacy in AD. Overall, combining a better understanding of innate neuroimmunity in aging and disease with the aEVO hypothesis may help uncover novel mechanism of pathogenesis of AD, leading to improved diagnostics and treatments.
在阿尔茨海默病(AD)中,淀粉样蛋白生成蛋白(APs),如β-淀粉样蛋白(Aβ)和tau蛋白,可能作为警报素/损伤相关分子模式(DAMPs)来刺激神经炎症和细胞死亡。事实上,最近的证据表明,脑特异性2型免疫网络可能在调节淀粉样蛋白生成和脑内稳态中起重要作用。对此至关重要的是,先天性神经免疫信号的成分,特别是2型成分,在调节免疫稳态和脑功能中发挥着明显特殊的作用。虽然平衡的免疫监视源于正常的2型脑免疫功能、小胶质细胞对聚集错误折叠蛋白的适当清除以及神经营养和突触营养信号,但警报素引发的异常促炎活动可能会破坏这种正常的免疫稳态,导致小胶质细胞对淀粉样蛋白的清除减少、突触丧失,并最终导致神经退行性变。此外,由于炎症增加可能反过来导致神经退行性变,预计AP聚集和神经炎症可能协同促进更多的损伤。在进化过程中尚未被淘汰的维持这种不利生物学状态的原因仍不清楚。在这里,我们从淀粉样蛋白生成可进化性的角度,即aEVO,一种关于AP聚集体对环境应激适应的假说观点,来讨论这些问题。推测地说,AP聚集和神经炎症在繁殖中对aEVO的相互作用,这在进化上是有益的,可能会成为一种通过拮抗多效性促进AD发病机制的共同激活关系。如果得到验证,同时抑制AP聚集和特定的先天性神经炎症可能会大大提高AD的治疗效果。总体而言,将对衰老和疾病中先天性神经免疫的更好理解与aEVO假说相结合,可能有助于揭示AD发病机制的新机制,从而改善诊断和治疗。